Immunoassay Market by Product & Service (Reagents & Kits, Analyzers, Software, Services), Technique (ELISA, Rapid Test), Application (Infectious Diseases, Endocrinology, Oncology), End User (Clinical Labs, Hospitals) - Global Forecast to 2021
出 版 商：MarketsandMarkets
出版日期：2016/11/18
頁 數：208頁
文件格式：PDF
價 格：
USD 5,650 (Single-User License)
USD 6,650 (Multi-User License)
USD 10,000 (Global-User License)
USD 6,650 (Multi-User License)
USD 10,000 (Global-User License)
The immunoassay market is expected to reach USD 25.45 billion by 2021 from USD 17.16 billion in 2016 at a CAGR of 8.2%. The global immunoassay market is segmented based on product & service, technology, application, end user, and region. The reagents & kits segment is expected to account for the largest market share of the immunoassay market during the forecast period. The high growth in this segment can be attributed to the expanding use of immunoassay tests worldwide.
On the basis of technology, the ELISA segment is expected to account for the largest share of the market in 2016. Expanding use of immunoassay tests in cancer, point-of-care in vitro diagnostics, infectious disease testing, and therapeutic drug level monitoring as well as the introduction of novel biomarkers will drive the growth of this market.
On the basis of application, the market is segmented into infectious diseases, endocrinology, bone and mineral disorders, oncology, cardiology, hematology and blood screening, autoimmune diseases, toxicology, neonatal screening, and other applications. The rise in incidence of HIV, tuberculosis, hepatitis, and other hospital-acquired infections has fueled the demand for immunoassay tests in the infectious diseases segment.
Geographically, the immunoassay market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). Growth in the North American region is primarily driven by rapidly increasing aging population and the concomitant rise in the prevalence of diseases as well as the growing life expectancy.
The major factors contributing to the growth of the immunoassay market include rising incidences of chronic diseases, extensive use of immunoassays in oncology, technological advancements, cost-effectiveness & rapid analysis of immunoassays.
The major players in this market include F. Hoffmann-La Roche Ltd. (Switzerland), Siemens AG (Germany), Abbott Laboratories, Inc. (U.S.), Beckman Coulter, Inc. (U.S.), Ortho-Clinical Diagnostics, Inc. (U.S.), and bioMerieux SA (France).
Research Coverage:
Apart from comprehensive geographic and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by the market players to maintain and increase their shares in the market. The abovementioned market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful in the immunoassay market.
Reasons to Buy the Report:
This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.
The report provides insights on the following pointers:
‧ Market Penetration: Comprehensive information on the product portfolios of the top players in the immunoassay market. The report analyses the immunoassay market by product & service, technology, application, end user, and region
‧ Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and new product launches in the immunoassay market
‧ Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the immunoassay market
‧ Market Development: Comprehensive information about emerging markets. This report analyses the market for various immunoassay products across geographies
‧ Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the immunoassay market
On the basis of technology, the ELISA segment is expected to account for the largest share of the market in 2016. Expanding use of immunoassay tests in cancer, point-of-care in vitro diagnostics, infectious disease testing, and therapeutic drug level monitoring as well as the introduction of novel biomarkers will drive the growth of this market.
On the basis of application, the market is segmented into infectious diseases, endocrinology, bone and mineral disorders, oncology, cardiology, hematology and blood screening, autoimmune diseases, toxicology, neonatal screening, and other applications. The rise in incidence of HIV, tuberculosis, hepatitis, and other hospital-acquired infections has fueled the demand for immunoassay tests in the infectious diseases segment.
Geographically, the immunoassay market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). Growth in the North American region is primarily driven by rapidly increasing aging population and the concomitant rise in the prevalence of diseases as well as the growing life expectancy.
The major factors contributing to the growth of the immunoassay market include rising incidences of chronic diseases, extensive use of immunoassays in oncology, technological advancements, cost-effectiveness & rapid analysis of immunoassays.
The major players in this market include F. Hoffmann-La Roche Ltd. (Switzerland), Siemens AG (Germany), Abbott Laboratories, Inc. (U.S.), Beckman Coulter, Inc. (U.S.), Ortho-Clinical Diagnostics, Inc. (U.S.), and bioMerieux SA (France).
Research Coverage:
Apart from comprehensive geographic and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by the market players to maintain and increase their shares in the market. The abovementioned market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful in the immunoassay market.
Reasons to Buy the Report:
This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.
The report provides insights on the following pointers:
‧ Market Penetration: Comprehensive information on the product portfolios of the top players in the immunoassay market. The report analyses the immunoassay market by product & service, technology, application, end user, and region
‧ Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and new product launches in the immunoassay market
‧ Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the immunoassay market
‧ Market Development: Comprehensive information about emerging markets. This report analyses the market for various immunoassay products across geographies
‧ Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the immunoassay market
TABLE OF CONTENTS
1 INTRODUCTION 16
1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.2.1 MARKETS COVERED 17
1.2.2 YEARS CONSIDERED FOR THE STUDY 19
1.3 CURRENCY 19
1.4 LIMITATIONS 19
1.5 STAKEHOLDERS 20
2 RESEARCH METHODOLOGY 21
2.1 SECONDARY DATA 22
2.1.1 KEY DATA FROM SECONDARY SOURCES 22
2.2 PRIMARY DATA 23
2.2.1 KEY DATA FROM PRIMARY SOURCES 24
2.3 MARKET SIZE ESTIMATION 24
2.3.1 BOTTOM-UP APPROACH 25
2.3.2 TOP-DOWN APPROACH 26
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 27
2.5 ASSUMPTIONS FOR THE STUDY 27
3 EXECUTIVE SUMMARY 28
3.1 INTRODUCTION 28
3.2 CONCLUSION 32
4 PREMIUM INSIGHTS 33
4.1 THE IMMUNOASSAY MARKET IS PROJECTED TO GROW AT A ROBUST GROWTH RATE FROM 2016 TO 2021 33
4.2 GEOGRAPHIC ANALYSIS: GLOBAL IMMUNOASSAY MARKET, BY PRODUCT AND SERVICE 34
4.3 GLOBAL IMMUNOASSAY MARKET, BY TECHNOLOGY 34
4.4 GEOGRAPHICAL SNAPSHOT OF THE GLOBAL IMMUNOASSAY MARKET 35
4.5 GLOBAL IMMUNOASSAY MARKET, BY APPLICATION 35
4.6 GLOBAL IMMUNOASSAY MARKET, BY END USER 36
4.7 LIFECYCLE ANALYSIS, BY REGION 36
5 MARKET OVERVIEW 37
5.1 INTRODUCTION 38
5.2 MARKET DYNAMICS 38
5.2.1 IMMUNOASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 38
5.2.2 DRIVERS 39
5.2.2.1 Growing Prevalence of Infectious and Chronic Diseases 39
5.2.2.2 Extensive Use of Immunoassays in Oncology 41
5.2.2.3 Technological Advancements 42
5.2.2.4 Cost-effectiveness & Rapid Analysis 42
5.2.2.5 Growth in the Biotechnology and Pharmaceutical Sector 42
5.2.3 RESTRAINTS 43
5.2.3.1 Low Detection Limit of Immunoassays 43
5.2.3.2 Implementation of Excise Duty By the U.S. Government 43
5.2.3.3 Stringent Regulations 43
5.2.4 OPPORTUNITIES 44
5.2.4.1 Integration of Microfluidics in Immunoassays 44
5.2.4.2 Point-of-care Testing with Multiplex Assay 44
5.2.4.3 Emerging Economies 45
5.2.5 CHALLENGES 45
5.2.5.1 Pricing Pressure on Manufacturers 45
6 IMMUNOASSAY MARKET, BY TECHNOLOGY 46
6.1 INTRODUCTION 47
6.2 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 48
6.2.1 ELISA MARKET, BY PLATFORM 50
6.2.1.1 Chemiluminescence Immunoassays (CLIA) 50
6.2.1.2 Fluorescence Immunoassays (FIA) 51
6.2.1.3 Colorimetric Immunoassay (CI) 52
6.2.2 ELISA MARKET, BY TYPE 54
6.2.2.1 First Generation 54
6.2.2.2 Second Generation 55
6.2.2.3 Third Generation 56
6.2.2.4 Fourth Generation and above 57
6.3 RAPID TESTS 58
6.4 WESTERN BLOT 59
6.5 ELISPOT 60
6.6 RADIOIMMUNOASSAYS (RIA) 61
6.7 POLYMERASE CHAIN REACTION (PCR) 62
7 IMMUNOASSAY MARKET, BY PRODUCT AND SERVICE 63
7.1 INTRODUCTION 64
7.2 REAGENTS & KITS 65
7.2.1 BY TYPE 67
7.2.1.1 Enzyme-linked Immunosorbent Assay (ELISA) Reagents and Kits 67
7.2.1.2 Rapid Test Reagents and Kits 68
7.2.1.3 Western Blot Reagents and Kits 69
7.2.1.4 ELISPOT Reagents and kits 70
7.2.1.5 RIA Reagents and Kits 71
7.2.1.6 PCR Reagents and Kits 72
7.3 ANALYZERS 73
7.3.1 BY PURCHASE MODE 74
7.3.1.1 Reagent Rental Purchase 74
7.3.1.2 Outright Purchase 76
7.3.2 BY TYPE 77
7.3.2.1 Open-ended systems 77
7.3.2.2 Closed-ended systems 78
7.4 SOFTWARE AND SERVICES 79
8 IMMUNOASSAY MARKET, BY APPLICATION 81
8.1 INTRODUCTION 82
8.2 INFECTIOUS DISEASES 83
8.3 ENDOCRINOLOGY 85
8.4 BONE AND MINERAL DISORDERS 87
8.5 ONCOLOGY 88
8.6 CARDIOLOGY 90
8.7 HEMATOLOGY AND BLOOD SCREENING 91
8.8 AUTOIMMUNE DISORDERS 92
8.9 TOXICOLOGY 94
8.10 NEONATAL SCREENING 95
8.11 OTHER APPLICATIONS 96
9 IMMUNOASSAY MARKET, BY END USER 98
9.1 INTRODUCTION 99
9.2 HOSPITALS 100
9.3 CLINICAL LABORATORIES 102
9.4 BLOOD BANKS 103
9.5 RESEARCH & ACADEMIC LABORATORIES 104
9.6 PHARMACEUTICAL COMPANIES, CROS, AND BIOTECHNOLOGY COMPANIES 105
9.7 OTHER END USERS 106
10 IMMUNOASSAY MARKET, BY REGION 108
10.1 INTRODUCTION 109
10.2 NORTH AMERICA 112
10.2.1 U.S. 116
10.2.2 CANADA 119
10.2.3 MEXICO 121
10.3 EUROPE 124
10.3.1 GERMANY 127
10.3.2 FRANCE 130
10.3.3 U.K. 132
10.3.4 ITALY 135
10.3.5 SPAIN 137
10.3.6 REST OF EUROPE (ROE) 139
10.4 ASIA 142
10.4.1 JAPAN 145
10.4.2 CHINA 148
10.4.3 INDIA 150
10.4.4 SOUTH KOREA 153
10.4.5 TAIWAN 155
10.4.6 REST OF ASIA (ROA) 157
10.5 REST OF THE WORLD (ROW) 160
11 COMPETITIVE LANDSCAPE 164
11.1 INTRODUCTION 164
11.2 STRATEGIC OVERVIEW 164
11.3 MARKET SHARE ANALYSIS 165
11.4 COMPETITIVE SITUATION AND TRENDS 166
11.4.1 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 167
11.4.2 REGULATORY APPROVALS 168
11.4.3 EXPANSIONS 169
11.4.4 PRODUCT LAUNCHES 170
11.4.5 ACQUISITIONS 171
12 COMPANY PROFILES 172
(Overview, Products and Services, Financials, Strategy & Development)*
12.1 INTRODUCTION 172
12.2 F. HOFFMANN-LA ROCHE LTD. 173
12.3 BECKMAN COULTER, INC. (SUBSIDIARY OF DANAHER CORPORATION) 176
12.4 BIO-RAD LABORATORIES, INC. 179
12.5 SIEMENS AG 181
12.6 SYSMEX CORPORATION 183
12.7 BIOMERIEUX SA 186
12.8 ALERE INC. 188
12.9 BECTON, DICKINSON AND COMPANY 191
12.10 ORTHO CLINICAL DIAGNOSTICS, INC. 193
12.11 ABBOTT LABORATORIES, INC. 194
*Details on Overview, Products and Services, Financials, Strategy & Development might not be Captured in case of Unlisted Companies.
13 APPENDIX 196
13.1 INSIGHTS OF INDUSTRY EXPERTS 196
13.2 DISCUSSION GUIDE 197
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 200
13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 202
13.5 AVAILABLE CUSTOMIZATIONS 204
13.6 RELATED REPORTS 204
1 INTRODUCTION 16
1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.2.1 MARKETS COVERED 17
1.2.2 YEARS CONSIDERED FOR THE STUDY 19
1.3 CURRENCY 19
1.4 LIMITATIONS 19
1.5 STAKEHOLDERS 20
2 RESEARCH METHODOLOGY 21
2.1 SECONDARY DATA 22
2.1.1 KEY DATA FROM SECONDARY SOURCES 22
2.2 PRIMARY DATA 23
2.2.1 KEY DATA FROM PRIMARY SOURCES 24
2.3 MARKET SIZE ESTIMATION 24
2.3.1 BOTTOM-UP APPROACH 25
2.3.2 TOP-DOWN APPROACH 26
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 27
2.5 ASSUMPTIONS FOR THE STUDY 27
3 EXECUTIVE SUMMARY 28
3.1 INTRODUCTION 28
3.2 CONCLUSION 32
4 PREMIUM INSIGHTS 33
4.1 THE IMMUNOASSAY MARKET IS PROJECTED TO GROW AT A ROBUST GROWTH RATE FROM 2016 TO 2021 33
4.2 GEOGRAPHIC ANALYSIS: GLOBAL IMMUNOASSAY MARKET, BY PRODUCT AND SERVICE 34
4.3 GLOBAL IMMUNOASSAY MARKET, BY TECHNOLOGY 34
4.4 GEOGRAPHICAL SNAPSHOT OF THE GLOBAL IMMUNOASSAY MARKET 35
4.5 GLOBAL IMMUNOASSAY MARKET, BY APPLICATION 35
4.6 GLOBAL IMMUNOASSAY MARKET, BY END USER 36
4.7 LIFECYCLE ANALYSIS, BY REGION 36
5 MARKET OVERVIEW 37
5.1 INTRODUCTION 38
5.2 MARKET DYNAMICS 38
5.2.1 IMMUNOASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 38
5.2.2 DRIVERS 39
5.2.2.1 Growing Prevalence of Infectious and Chronic Diseases 39
5.2.2.2 Extensive Use of Immunoassays in Oncology 41
5.2.2.3 Technological Advancements 42
5.2.2.4 Cost-effectiveness & Rapid Analysis 42
5.2.2.5 Growth in the Biotechnology and Pharmaceutical Sector 42
5.2.3 RESTRAINTS 43
5.2.3.1 Low Detection Limit of Immunoassays 43
5.2.3.2 Implementation of Excise Duty By the U.S. Government 43
5.2.3.3 Stringent Regulations 43
5.2.4 OPPORTUNITIES 44
5.2.4.1 Integration of Microfluidics in Immunoassays 44
5.2.4.2 Point-of-care Testing with Multiplex Assay 44
5.2.4.3 Emerging Economies 45
5.2.5 CHALLENGES 45
5.2.5.1 Pricing Pressure on Manufacturers 45
6 IMMUNOASSAY MARKET, BY TECHNOLOGY 46
6.1 INTRODUCTION 47
6.2 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 48
6.2.1 ELISA MARKET, BY PLATFORM 50
6.2.1.1 Chemiluminescence Immunoassays (CLIA) 50
6.2.1.2 Fluorescence Immunoassays (FIA) 51
6.2.1.3 Colorimetric Immunoassay (CI) 52
6.2.2 ELISA MARKET, BY TYPE 54
6.2.2.1 First Generation 54
6.2.2.2 Second Generation 55
6.2.2.3 Third Generation 56
6.2.2.4 Fourth Generation and above 57
6.3 RAPID TESTS 58
6.4 WESTERN BLOT 59
6.5 ELISPOT 60
6.6 RADIOIMMUNOASSAYS (RIA) 61
6.7 POLYMERASE CHAIN REACTION (PCR) 62
7 IMMUNOASSAY MARKET, BY PRODUCT AND SERVICE 63
7.1 INTRODUCTION 64
7.2 REAGENTS & KITS 65
7.2.1 BY TYPE 67
7.2.1.1 Enzyme-linked Immunosorbent Assay (ELISA) Reagents and Kits 67
7.2.1.2 Rapid Test Reagents and Kits 68
7.2.1.3 Western Blot Reagents and Kits 69
7.2.1.4 ELISPOT Reagents and kits 70
7.2.1.5 RIA Reagents and Kits 71
7.2.1.6 PCR Reagents and Kits 72
7.3 ANALYZERS 73
7.3.1 BY PURCHASE MODE 74
7.3.1.1 Reagent Rental Purchase 74
7.3.1.2 Outright Purchase 76
7.3.2 BY TYPE 77
7.3.2.1 Open-ended systems 77
7.3.2.2 Closed-ended systems 78
7.4 SOFTWARE AND SERVICES 79
8 IMMUNOASSAY MARKET, BY APPLICATION 81
8.1 INTRODUCTION 82
8.2 INFECTIOUS DISEASES 83
8.3 ENDOCRINOLOGY 85
8.4 BONE AND MINERAL DISORDERS 87
8.5 ONCOLOGY 88
8.6 CARDIOLOGY 90
8.7 HEMATOLOGY AND BLOOD SCREENING 91
8.8 AUTOIMMUNE DISORDERS 92
8.9 TOXICOLOGY 94
8.10 NEONATAL SCREENING 95
8.11 OTHER APPLICATIONS 96
9 IMMUNOASSAY MARKET, BY END USER 98
9.1 INTRODUCTION 99
9.2 HOSPITALS 100
9.3 CLINICAL LABORATORIES 102
9.4 BLOOD BANKS 103
9.5 RESEARCH & ACADEMIC LABORATORIES 104
9.6 PHARMACEUTICAL COMPANIES, CROS, AND BIOTECHNOLOGY COMPANIES 105
9.7 OTHER END USERS 106
10 IMMUNOASSAY MARKET, BY REGION 108
10.1 INTRODUCTION 109
10.2 NORTH AMERICA 112
10.2.1 U.S. 116
10.2.2 CANADA 119
10.2.3 MEXICO 121
10.3 EUROPE 124
10.3.1 GERMANY 127
10.3.2 FRANCE 130
10.3.3 U.K. 132
10.3.4 ITALY 135
10.3.5 SPAIN 137
10.3.6 REST OF EUROPE (ROE) 139
10.4 ASIA 142
10.4.1 JAPAN 145
10.4.2 CHINA 148
10.4.3 INDIA 150
10.4.4 SOUTH KOREA 153
10.4.5 TAIWAN 155
10.4.6 REST OF ASIA (ROA) 157
10.5 REST OF THE WORLD (ROW) 160
11 COMPETITIVE LANDSCAPE 164
11.1 INTRODUCTION 164
11.2 STRATEGIC OVERVIEW 164
11.3 MARKET SHARE ANALYSIS 165
11.4 COMPETITIVE SITUATION AND TRENDS 166
11.4.1 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 167
11.4.2 REGULATORY APPROVALS 168
11.4.3 EXPANSIONS 169
11.4.4 PRODUCT LAUNCHES 170
11.4.5 ACQUISITIONS 171
12 COMPANY PROFILES 172
(Overview, Products and Services, Financials, Strategy & Development)*
12.1 INTRODUCTION 172
12.2 F. HOFFMANN-LA ROCHE LTD. 173
12.3 BECKMAN COULTER, INC. (SUBSIDIARY OF DANAHER CORPORATION) 176
12.4 BIO-RAD LABORATORIES, INC. 179
12.5 SIEMENS AG 181
12.6 SYSMEX CORPORATION 183
12.7 BIOMERIEUX SA 186
12.8 ALERE INC. 188
12.9 BECTON, DICKINSON AND COMPANY 191
12.10 ORTHO CLINICAL DIAGNOSTICS, INC. 193
12.11 ABBOTT LABORATORIES, INC. 194
*Details on Overview, Products and Services, Financials, Strategy & Development might not be Captured in case of Unlisted Companies.
13 APPENDIX 196
13.1 INSIGHTS OF INDUSTRY EXPERTS 196
13.2 DISCUSSION GUIDE 197
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 200
13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 202
13.5 AVAILABLE CUSTOMIZATIONS 204
13.6 RELATED REPORTS 204
